RPL3P12: A Drug Target / Disease Biomarker (G100131358)

Target Name: RPL3P12

NCBI ID: G100131358

RPL3P12

Other Name(s): Ribosomal protein L3 pseudogene 12 | ribosomal protein L3 pseudogene 12 | RPL3_3_1807

RPL3P12: A Drug Target / Disease Biomarker

RPL3P12 is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 12 and has been shown to play a role in the regulation of mitochondrial function and energy metabolism.

Mitochondria are organelles that are found in the cells of all eukaryotes, including humans. They are responsible for generating the majority of the energy that the cells use to function, and they are also involved in the production of the molecules that are used to build and maintain the cell. In addition, mitochondria are also involved in the regulation of the cell's DNA, as well as the translation of that DNA into proteins.

The RPL3P12 gene is associated with a number of different diseases, including cancer. Studies have shown that RPL3P12 is often expressed in tissues that are affected by cancer, and that it is involved in the regulation of processes that are commonly disrupted in cancer cells.

One of the key functions of RPL3P12 is its role in regulating mitochondrial function. Mitochondria are critical for the production of energy in the cell, and they are also involved in the regulation of the cell's metabolism. The RPL3P12 gene has been shown to play a role in the regulation of mitochondrial ATP synthase, a protein that is involved in the production of ATP, the cell's primary energy source.

In addition to its role in mitochondrial function, RPL3P12 has also been shown to be involved in the regulation of the cell's DNA. Studies have shown that RPL3P12 is often expressed in tissues that are affected by cancer, and that it is involved in the regulation of processes that are commonly disrupted in cancer cells.

One of the ways that RPL3P12 is involved in the regulation of DNA is through its role in the transcription of genes. The RPL3P12 gene is known to encode a protein that is involved in the transcription of DNA into RNA. This protein has been shown to play a role in the regulation of gene expression, and it is possible that it may be involved in the regulation of cancer cell growth and progression.

Another way that RPL3P12 is involved in the regulation of DNA is through its role in the regulation of DNA replication. The RPL3P12 gene is also known to encode a protein that is involved in the regulation of DNA replication, a process that is important for the maintenance of the cell's genetic material.

In addition to its role in the regulation of DNA, RPL3P12 has also been shown to play a role in the regulation of mitochondrial function. Studies have shown that RPL3P12 is involved in the regulation of mitochondrial proton motive force, a protein that is involved in the production of ATP in the cell.

Overall, the RPL3P12 gene is a promising drug target or biomarker for the treatment of various diseases, including cancer. Its role in the regulation of mitochondrial function and energy metabolism, as well as its involvement in the regulation of DNA, make it a potential target for small molecules that can be used to inhibit its activity. Further research is needed to fully understand the role of RPL3P12 in the treatment of disease.

Protein Name: Ribosomal Protein L3 Pseudogene 12

The "RPL3P12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL3P12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets